Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) Target Price at $20.50

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.50.

Several research analysts have recently commented on TARA shares. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price objective on the stock in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, April 28th. Finally, Scotiabank initiated coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price for the company.

Protara Therapeutics Stock Performance

Shares of NASDAQ TARA traded up $0.13 during trading on Friday, hitting $3.46. The company had a trading volume of 243,611 shares, compared to its average volume of 344,740. The stock has a 50 day simple moving average of $3.13 and a 200 day simple moving average of $3.76. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48. The firm has a market capitalization of $133.49 million, a P/E ratio of -2.01 and a beta of 1.35.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.18. As a group, analysts predict that Protara Therapeutics will post -3.32 EPS for the current year.

Institutional Trading of Protara Therapeutics

Several institutional investors have recently made changes to their positions in TARA. Walleye Capital LLC grew its holdings in Protara Therapeutics by 3.9% during the 1st quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock valued at $977,000 after buying an additional 8,640 shares in the last quarter. Geode Capital Management LLC grew its holdings in Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after buying an additional 9,553 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Protara Therapeutics during the 1st quarter valued at approximately $64,000. Commonwealth Equity Services LLC grew its holdings in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares in the last quarter. Finally, HBK Investments L P purchased a new position in Protara Therapeutics during the 4th quarter valued at approximately $106,000. Hedge funds and other institutional investors own 38.13% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.